Navigation Links
Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
Date:8/27/2008

ANTONY, France, August 27 /PRNewswire-FirstCall/ -- The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved STALLERGENES' half year consolidated financial statements:

(EUR millions) 2007 HY1 2008 HY1 08/07

% of % of %

sales sales change

Sales 74.8 100.0 87.0 100.0 16

Cost of sales (16.9) (22.5) (19.9) (22.8) 18

Gross profit 57.9 77.5 67.1 77.2 16

General, administrative and selling (31.3) (41.9) (35.1) (40.3) 12

expenses

Gross operating profit before R&D 26.6 35.6 32.1 36.8 21

R&D (11.2) (15.0) (13.7) (15.7) 22

EBIT 15.4 20.6 18.4 13.8 19

Net profit (Group share) 10.1 13.6 12.0 13.8 19

Net borrowings 9.3 4.2 (54)

Sales growth and financial position

The first half of 2008 witnessed a marked increase in operating profitability, which benefited from sales growth. Gross profit as a percentage of sales remained stable at 77%.

R&D expenses were up 22%, reflecting the stepped-up allergen tablet development programme.

Operating profit totalled EUR 18.4 million, an increase of 19% that showed a further improvement in operating profit margin to 21.1% of sales.

Net profit concurrently increased by 19% to EUR 12 million.

The financial position improved: net borrowings declined by 54% and now only represent 6% of equity, compared to 17% at end June 2007 (16% at 31 December 2007).

Significant HY1 2008 transactions and events

On 24 June 2008, Stallergenes was granted the mark
'/>"/>

SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
2. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
3. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
4. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
5. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
6. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
7. Natures Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity
8. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
9. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
10. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... ChanTest, the leading expert in ion channels and ... development, and safety -- is one of eight organizations ... and Commercialization Program. Governor Ted Strickland and Interim Director ... the Ohio Third Frontier Commission, Mark Barbash, announced the ...
... Aegera Therapeutics is pleased to announce the initiation ... AEG33773, a novel, orally bio-available small molecule therapeutic ... , The Phase 2a study, entitled A Multicenter, ... Efficacy of AEG33773 versus Placebo in Patients with ...
... May 6 iZumi Bio, Inc., a biotechnology ... stem cell (iPS) technology with the mission of ... differentiation of patient cells, today announced the appointments ... (CTO) and Dushyant Pathak, Ph.D., as vice president ...
Cached Biology Technology:ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 3
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
(Date:4/17/2014)... Australian National University (ANU), have developed a new ... variability over the past 5.3 million years., The ... surrounding ice ages over the past two million ... carbon dioxide levels, global temperatures and sea levels., ... (UoS) and the National Oceanography Centre (NOC) in ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Ancient sea-levels give new clues on ice ages 2
... in marine mammals, brains reveals that these animals are ... DDTs and PCBs, as well as emerging contaminants such ... lead author on the study currently in press and ... performed the research as a student in the Woods ...
... radio landscape has made it tough for Foghat to get ... to new research published in The American Naturalist . ... that the songs of white-crowned sparrows change over time in ... factors that drive the evolution of mating signals in birds. ...
... Institutes of Health is launching the first integrated, ... rare and neglected diseases. The $24 million program ... Rare and Neglected Diseases Program, or TRND. ... is unusual because TRND creates a drug development ...
Cached Biology News:Skip this cocktail party 2Skip this cocktail party 3Bird songs change with environment 2NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
Request Info...
Request Info...
Biology Products: